Novo Nordisk (CPSE:NOVO B) received US FDA approval for Awiqli as a once weekly basal insulin for children with type 2 diabetes. Awiqli is indicated as an adjunct to diet and exercise for patients aged 10 years and older requiring long acting insulin treatment. The product introduces a weekly dosing option that may reduce injection frequency for pediatric type 2 diabetes compared with daily basal insulin regimens. The Awiqli approval for children with type 2 diabetes sits alongside deeper trends in Novo Nordisk's diabetes pipeline uncovered by our work. Our analysis turns up 2 warning signs (1 major) for Novo Nordisk as well.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.